NCT04465487CompletedPhase 1
Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Sept 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- First submitted
- 30 Aug 2024
- Start date
- 11 Aug 2021
- Lead sponsor
- Regeneron Pharmaceuticals Inc.
- Diseases
- Head and neck cancer
- NCT number
- NCT04465487
- EU CT number
- 2022-500868-36-00
- EudraCT number
- 2020-000075-20
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 19
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Institut Catala D'oncologia Coordinator of this site? Confirm its status | L'Hospitalet de Llobregat | Spain | Completed |
| Hospital Universitario HM Sanchinarro Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Ramón y Cajal Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.